Orris

Pharmacology : antihypertensive, heart failure mcqs, saqs laqs with answrs

Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
I now have enough high-quality content from Goodman & Gilman's and Harrison's to generate a thorough question bank. Let me compile it now.

Pharmacology: Antihypertensive & Heart Failure — Complete Question Bank

Sources: Goodman & Gilman's The Pharmacological Basis of Therapeutics; Harrison's Principles of Internal Medicine 22E; Braunwald's Heart Disease; Brenner & Rector's The Kidney

SECTION A — MULTIPLE CHOICE QUESTIONS (MCQs)

ANTIHYPERTENSIVES

Q1. A 55-year-old man with hypertension develops a dry, irritating cough after starting a new medication. Which drug is most likely responsible?
  • A) Losartan
  • B) Amlodipine
  • C) Lisinopril
  • D) Hydrochlorothiazide
Answer: C) Lisinopril ACE inhibitors (e.g., lisinopril, enalapril, ramipril) cause cough in ~5% of patients due to accumulation of bradykinin and substance P. ARBs (losartan) do NOT cause cough, making them the preferred alternative. (Goodman & Gilman's, Table 33-2)
Q2. Which antihypertensive class is the FIRST-LINE choice in a hypertensive patient with proteinuric diabetic nephropathy?
  • A) Calcium channel blockers
  • B) Thiazide diuretics
  • C) ACE inhibitors or ARBs
  • D) Beta-blockers
Answer: C) ACE inhibitors or ARBs ACE inhibitors and ARBs reduce intraglomerular pressure by dilating the efferent arteriole, lowering proteinuria and slowing CKD progression, independent of their blood pressure-lowering effect. (Goodman & Gilman's; Harrison's 22E)
Q3. A patient on hydrochlorothiazide presents with weakness and ECG changes. Serum K+ is 2.8 mEq/L. The mechanism of hypokalemia is:
  • A) Increased aldosterone secretion → increased K+ reabsorption
  • B) Inhibition of Na+-K+-2Cl- symporter in the loop of Henle
  • C) Increased delivery of Na+ to the distal tubule → increased K+ secretion via aldosterone
  • D) Direct inhibition of the Na/K-ATPase pump
Answer: C) Increased delivery of Na+ to the distal tubule → increased K+ secretion via aldosterone Thiazides block the Na+-Cl- cotransporter in the distal convoluted tubule, increasing Na+ delivery to the collecting duct where aldosterone promotes Na+/K+ exchange, causing K+ loss.
Q4. Which calcium channel blocker is most CARDIOSELECTIVE (preferentially acts on the AV node) and is used to reduce heart rate?
  • A) Amlodipine
  • B) Nifedipine
  • C) Verapamil
  • D) Felodipine
Answer: C) Verapamil Verapamil (and diltiazem) are non-dihydropyridine CCBs with strong cardiac selectivity, slowing SA and AV node conduction. Dihydropyridines (amlodipine, nifedipine, felodipine) are predominantly vascular. (Harrison's 22E, Table 288-4)
Q5. Bilateral renal artery stenosis is an absolute contraindication to which drug class?
  • A) Beta-blockers
  • B) ACE inhibitors
  • C) Thiazide diuretics
  • D) Calcium channel blockers
Answer: B) ACE inhibitors In bilateral RAS, the GFR is maintained by AngII-mediated efferent arteriolar constriction. ACE inhibitors abolish this mechanism, precipitating acute kidney failure. (Goodman & Gilman's)
Q6. Which antihypertensive is preferred in pregnancy-induced hypertension?
  • A) Enalapril
  • B) Losartan
  • C) Methyldopa or labetalol
  • D) Hydrochlorothiazide
Answer: C) Methyldopa or labetalol ACE inhibitors and ARBs are teratogenic (fetal renal dysgenesis) and absolutely contraindicated in pregnancy. Methyldopa and labetalol have the longest safety records in obstetric use. (Creasy & Resnik's Maternal-Fetal Medicine)
Q7. A patient with hypertension and gout worsens after starting a diuretic. Which diuretic is most likely responsible and what is the mechanism?
  • A) Spironolactone - increases uric acid synthesis
  • B) Furosemide - blocks xanthine oxidase
  • C) Hydrochlorothiazide - reduces uric acid excretion via competition at the organic anion transporter
  • D) Acetazolamide - alkalinizes urine
Answer: C) Hydrochlorothiazide - reduces uric acid excretion via competition at the organic anion transporter Thiazides competitively inhibit uric acid secretion at the proximal tubule organic anion transporter, raising serum uric acid and precipitating gout in predisposed patients.
Q8. Nebivolol differs from other beta-blockers in that it:
  • A) Blocks both alpha and beta receptors
  • B) Releases nitric oxide causing vasodilation
  • C) Is non-selective with membrane stabilizing activity
  • D) Selectively blocks beta-2 receptors
Answer: B) Releases nitric oxide causing vasodilation Nebivolol is a third-generation beta-1 selective blocker with additional vasodilatory action via nitric oxide release. Carvedilol combines alpha + beta blockade. (Harrison's 22E)
Q9. Which drug causes reflex tachycardia as a notable side effect when used as an antihypertensive?
  • A) Atenolol
  • B) Diltiazem
  • C) Nifedipine (short-acting)
  • D) Verapamil
Answer: C) Nifedipine (short-acting) Rapid vasodilation with short-acting nifedipine triggers a baroreceptor-mediated reflex sympathetic surge causing tachycardia. This is why short-acting formulations are avoided for chronic hypertension.
Q10. The initial drug of choice for hypertension in a patient with a recent MI with reduced EF is:
  • A) Amlodipine alone
  • B) ACE inhibitor + beta-blocker
  • C) ARB + CCB
  • D) Thiazide + CCB
Answer: B) ACE inhibitor + beta-blocker Post-MI with reduced EF: ACE inhibitor reduces ventricular remodeling; beta-blocker reduces sympathetic activation, arrhythmia risk, and mortality. Both have level A evidence. (Goodman & Gilman's; Braunwald's Heart Disease)

HEART FAILURE

Q11. Which of the following best explains why ACE inhibitors improve survival in HFrEF?
  • A) Positive inotropy increasing cardiac output
  • B) Neurohumoral modulation reducing angiotensin II-mediated cardiac remodeling and afterload
  • C) Directly increasing renal blood flow
  • D) Blocking aldosterone receptors in the myocardium
Answer: B) Neurohumoral modulation reducing angiotensin II-mediated cardiac remodeling and afterload AngII causes vasoconstriction (increased afterload), aldosterone release (Na/water retention), and direct hypertrophic/fibrotic effects on cardiomyocytes. ACE inhibitors block all these. (Goodman & Gilman's, p. 672)
Q12. Sacubitril/valsartan (Entresto) is approved for heart failure. What is the mechanism of sacubitril?
  • A) Angiotensin receptor blockade
  • B) Neprilysin inhibition - prevents degradation of natriuretic peptides (ANP, BNP)
  • C) Direct renin inhibition
  • D) Aldosterone receptor antagonism
Answer: B) Neprilysin inhibition - prevents degradation of natriuretic peptides (ANP, BNP) Sacubitril (after deesterification) inhibits neprilysin, increasing ANP/BNP levels, promoting vasodilation, natriuresis, and anti-fibrotic/anti-hypertrophic effects. Valsartan simultaneously blocks AT1 receptors. (Goodman & Gilman's)
Q13. A patient with HFrEF on furosemide develops diuretic resistance. Which mechanism is MOST responsible for loop diuretic resistance in heart failure?
  • A) Increased renal blood flow
  • B) Compensatory hypertrophy of distal nephron segments with increased Na+ reabsorption
  • C) Inhibition of the collecting duct Na channels
  • D) Metabolic alkalosis blocking loop diuretic action
Answer: B) Compensatory hypertrophy of distal nephron segments with increased Na+ reabsorption Chronic loop diuretic use triggers adaptive hypertrophy of distal tubule cells, which reabsorb the extra Na+ delivered, blunting diuretic efficacy. Adding a thiazide can overcome this ("sequential nephron blockade").
Q14. According to major trials (RALES, EMPHASIS-HF), spironolactone/eplerenone reduce mortality in HFrEF by:
  • A) Increasing cardiac contractility
  • B) Blocking mineralocorticoid receptors - preventing cardiac fibrosis and remodeling
  • C) Enhancing beta-adrenergic responsiveness
  • D) Directly vasodilating coronary arteries
Answer: B) Blocking mineralocorticoid receptors - preventing cardiac fibrosis and remodeling Aldosterone causes myocardial fibrosis, endothelial dysfunction, and promotes arrhythmias. MRAs (spironolactone, eplerenone) block these effects, reducing hospitalizations and death in HFrEF. (Goodman & Gilman's; Braunwald's)
Q15. SGLT2 inhibitors (empagliflozin, dapagliflozin) improve outcomes in heart failure primarily through:
  • A) Positive inotropic effect on the myocardium
  • B) Osmotic diuresis and natriuresis reducing preload and afterload, plus direct cardioprotective effects
  • C) Beta-adrenergic receptor blockade
  • D) ACE inhibition
Answer: B) Osmotic diuresis and natriuresis reducing preload and afterload, plus direct cardioprotective effects SGLT2 inhibitors cause glucosuria-driven osmotic diuresis/natriuresis, reduce cardiac fibrosis, and improve myocardial energy metabolism. They are now a pillar of HFrEF and HFpEF treatment (Treatment Principle VI). (Goodman & Gilman's, 2025)
Q16. Digoxin improves symptoms in HFrEF through:
  • A) Beta-1 agonism increasing cAMP
  • B) Inhibition of Na+/K+-ATPase → increased intracellular Ca2+ → increased contractility
  • C) Opening K+ channels to hyperpolarize myocardium
  • D) Reducing preload via aldosterone blockade
Answer: B) Inhibition of Na+/K+-ATPase → increased intracellular Ca2+ → increased contractility Digoxin inhibits the Na+/K+ pump, raising intracellular Na+. The Na+/Ca2+ exchanger then reduces Ca2+ efflux, increasing intracellular Ca2+ and enhancing myocardial contractility (positive inotropy).
Q17. A patient with heart failure is started on carvedilol. Why are beta-blockers started at very low doses in heart failure?
  • A) Risk of hypokalemia with full doses
  • B) Acute negative inotropic effect may worsen decompensated failure
  • C) Beta-blockers cause fluid retention initially
  • D) Risk of angioedema
Answer: B) Acute negative inotropic effect may worsen decompensated failure In decompensated HF, sympathetic drive is maintaining cardiac output. Abrupt beta-blockade removes this compensation. Low doses are titrated slowly in stable patients to allow the heart to adapt while gaining long-term benefits (reduced remodeling, anti-arrhythmic effect).
Q18. Hydralazine + isosorbide dinitrate in heart failure is recommended specifically for:
  • A) White patients intolerant to diuretics
  • B) African American patients who remain symptomatic on ACE inhibitor + beta-blocker
  • C) Patients with preserved ejection fraction (HFpEF)
  • D) Hypertensive crisis management only
Answer: B) African American patients who remain symptomatic on ACE inhibitor + beta-blocker The A-HeFT trial showed significant mortality reduction with this combination specifically in self-identified African American patients. It is also used in patients who cannot tolerate ACE inhibitors/ARBs (e.g., renal failure, hyperkalemia). (Harrison's 22E; Goodman & Gilman's)
Q19. Ivabradine is used in heart failure to:
  • A) Block the If (funny current) in the SA node, reducing heart rate without affecting contractility
  • B) Increase cardiac contractility via PDE inhibition
  • C) Block calcium channels in vascular smooth muscle
  • D) Enhance K+ secretion in the distal tubule
Answer: A) Block the If (funny current) in the SA node, reducing heart rate without affecting contractility Ivabradine selectively inhibits the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel (If current) in the SA node. It reduces heart rate (Treatment Principle V) without negative inotropy - particularly useful in patients with resting HR >70 bpm on maximal beta-blocker.
Q20. Which drug should be AVOIDED in a patient with hypertension AND asthma?
  • A) Amlodipine
  • B) Propranolol
  • C) Losartan
  • D) Indapamide
Answer: B) Propranolol Propranolol is a non-selective beta-blocker. Blockade of beta-2 receptors in the bronchi causes bronchoconstriction, which can precipitate a fatal asthma attack. Cardioselective beta-1 blockers (atenolol, bisoprolol) are relatively safer but still used cautiously.

SECTION B — SHORT ANSWER QUESTIONS (SAQs)

SAQ 1. List the main classes of antihypertensive drugs and give one example from each class. (5 marks)
Answer:
ClassExample
ACE InhibitorsLisinopril, enalapril, ramipril
Angiotensin Receptor Blockers (ARBs)Losartan, valsartan, telmisartan
Calcium Channel Blockers (CCBs) - DihydropyridinesAmlodipine, nifedipine
CCBs - Non-dihydropyridinesVerapamil, diltiazem
Thiazide/Thiazide-like diureticsHydrochlorothiazide, indapamide, chlorthalidone
Beta-blockersAtenolol, bisoprolol, carvedilol, metoprolol
Mineralocorticoid Receptor Antagonists (MRAs)Spironolactone, eplerenone
Alpha-blockersDoxazosin, prazosin
Central alpha-2 agonistsMethyldopa, clonidine
Direct vasodilatorsHydralazine, minoxidil
(Harrison's 22E, Table 288-4)
SAQ 2. What are the "compelling indications" for ACE inhibitors? (4 marks)
Answer:
  1. Heart failure with reduced EF (HFrEF) - reduces mortality and remodeling
  2. Post-MI with LV dysfunction - reduces infarct expansion, ventricular remodeling
  3. Diabetic nephropathy / CKD with proteinuria - reduces intraglomerular hypertension and proteinuria
  4. Hypertension in high cardiovascular-risk patients (e.g., HOPE trial with ramipril)
Also considered: left ventricular hypertrophy, recurrent stroke prevention (combined with thiazide), microalbuminuria.
SAQ 3. What is the "Neurohormonal hypothesis" of heart failure and how does it guide pharmacotherapy? (5 marks)
Answer: Reduced cardiac output in HFrEF triggers compensatory activation of the sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system (RAAS), and vasopressin. Acutely, these mechanisms maintain BP and organ perfusion. Chronically, they cause:
  • Increased afterload (vasoconstriction)
  • Volume overload (Na/water retention by aldosterone and vasopressin)
  • Direct myocardial toxicity: AngII and norepinephrine cause cardiomyocyte hypertrophy, apoptosis, and fibrosis
Pharmacological targets:
  • ACE inhibitors/ARBs/ARNIs → block RAAS
  • Beta-blockers (carvedilol, bisoprolol, metoprolol) → block SNS
  • MRAs (spironolactone, eplerenone) → block aldosterone effects
  • Diuretics → relieve volume overload
  • SGLT2 inhibitors → additional natriuresis + cardioprotection
(Goodman & Gilman's, pp. 668-672)
SAQ 4. What are the side effects of spironolactone? (4 marks)
Answer:
  1. Hyperkalemia - most dangerous; monitor K+ closely, especially with ACEIs/ARBs
  2. Gynecomastia - antiandrogenic effect (spironolactone binds androgen receptors); painful breast enlargement in men
  3. Menstrual irregularities in women
  4. Renal insufficiency - with high doses or in patients with impaired renal function
  5. Metabolic acidosis (hyperchloremic)
Note: Eplerenone is a selective MRA without the antiandrogenic side effects, so it does not cause gynecomastia.
SAQ 5. Describe the mechanism of action of thiazide diuretics in hypertension. Why do they lose efficacy in GFR < 30 mL/min? (4 marks)
Answer: Thiazides inhibit the Na+-Cl- cotransporter (NCC) in the distal convoluted tubule (DCT), reducing Na+ reabsorption and increasing urinary Na+ and water excretion. Initially, this reduces plasma volume and cardiac output. Long-term, the main antihypertensive effect is via vascular smooth muscle relaxation (possibly due to reduced intracellular Na+/Ca2+ exchange).
They lose efficacy in advanced CKD (GFR < 30 mL/min) because:
  • Reduced tubular secretion of the drug (competes with organic anions) limits delivery to the nephron
  • Fewer functional DCT cells are available for drug action
  • Loop diuretics (furosemide, torsemide) are preferred in severe CKD due to their activity in a tubular segment still functional in CKD.
SAQ 6. What are the clinical features and management of a hypertensive emergency? (5 marks)
Answer: Definition: BP typically >180/120 mmHg with end-organ damage (differs from urgency which lacks end-organ damage).
End-organ involvement:
  • Brain: hypertensive encephalopathy, stroke, intracranial hemorrhage
  • Heart: acute coronary syndrome, acute heart failure/pulmonary edema
  • Kidney: acute kidney injury (hypertensive nephrosclerosis)
  • Eyes: papilledema, retinal hemorrhages
  • Aorta: aortic dissection
Management:
  • IV labetalol or nicardipine for most emergencies
  • IV sodium nitroprusside - rapid acting, used for severe cases (requires ICU monitoring; risk of cyanide toxicity)
  • IV nitroglycerine preferred if ACS or acute pulmonary edema
  • IV hydralazine in eclampsia
  • Goal: reduce MAP by no more than 25% in the first hour, then gradually to 160/100 over 2-6 hours (avoid overcorrection)
  • Exception: aortic dissection - target SBP <120 mmHg aggressively with IV labetalol/esmolol
(Rosen's Emergency Medicine)
SAQ 7. How does digoxin cause toxicity and what are its manifestations? (4 marks)
Answer: Mechanism of toxicity: Excessive inhibition of Na+/K+-ATPase increases intracellular Ca2+ to toxic levels, causing:
  • Delayed afterdepolarizations (DADs) → triggered arrhythmias
  • Increased vagal tone → bradycardia, AV block
Predisposing factors: Hypokalemia (K+ competes with digoxin for binding site; low K+ increases digoxin binding), hypomagnesemia, renal failure (digoxin is renally cleared), hypothyroidism.
Clinical manifestations:
  • Cardiac: Bradycardia, AV block, atrial tachycardia with block (pathognomonic), bidirectional ventricular tachycardia, ventricular fibrillation
  • GI: Nausea, vomiting, anorexia, abdominal pain
  • Neurological: Visual disturbances (yellow-green halos - xanthopsia), confusion, delirium, fatigue
Treatment: Digoxin-specific antibody fragments (Digibind/DigiFab) for severe toxicity; correction of K+/Mg2+ deficits; temporary pacing if severe bradycardia.

SECTION C — LONG ANSWER QUESTIONS (LAQs)

LAQ 1. Discuss the pharmacological management of Heart Failure with Reduced Ejection Fraction (HFrEF). Include mechanisms of action, evidence-based drug choices, and important adverse effects. (15 marks)
Answer:

Introduction

Heart failure is inability of the heart to pump blood commensurate with the body's metabolic needs, or doing so only at elevated filling pressures. HFrEF (EF < 40%) is characterized by reduced systolic function and is managed through 6 treatment principles. (Goodman & Gilman's)

Pathophysiological Basis

The neurohormonal model underpins all pharmacotherapy: reduced cardiac output activates the SNS, RAAS, and vasopressin - initially compensatory, chronically deleterious (cardiac hypertrophy, fibrosis, arrhythmias, and further depression of function).

Treatment Principle I: Neurohumoral Modulation

1. ACE Inhibitors (ACEIs)
  • Mechanism: Block conversion of AngI → AngII → reduce vasoconstriction, aldosterone, and direct myocardial fibrosis; also reduce bradykinin degradation (causes cough)
  • Drugs: Captopril, enalapril, lisinopril, ramipril
  • Evidence: CONSENSUS trial (enalapril) - 40% mortality reduction in NYHA Class IV. SOLVD trial - 16% reduction in mortality and 26% reduction in hospitalizations
  • Dosing (Goodman & Gilman's Table 33-2): Start low (e.g., enalapril 2×2.5 mg), titrate to target (2×20 mg)
  • Key adverse effects: Dry cough (~5%), hyperkalemia, angioedema (rare but potentially fatal), hypotension (especially 1st dose), worsening renal function in renal artery stenosis
  • Monitoring: BP, serum K+, creatinine at baseline and after dose changes
2. ARBs (Angiotensin Receptor Blockers)
  • Mechanism: Block AT1 receptors directly; do NOT block bradykinin degradation (no cough)
  • Drugs: Losartan, valsartan, candesartan
  • Use: Alternative to ACEIs in patients with ACEI-induced cough or angioedema; avoid combining ACEI + ARB (renal failure risk without addional mortality benefit)
3. ARNI: Sacubitril/Valsartan (Entresto)
  • Mechanism: Sacubitril inhibits neprilysin → prevents ANP/BNP degradation → vasodilation, natriuresis, anti-fibrotic effects; Valsartan blocks AT1 receptors
  • Evidence: PARADIGM-HF (McMurray et al., 2014) - sacubitril/valsartan superior to enalapril: 20% reduction in cardiovascular death/hospitalization
  • Indication: Replace ACEI/ARB in NYHA Class II-III patients tolerating an ACEI/ARB
  • Contraindication: Must have 36-hour washout from ACEIs before starting (risk of angioedema); contraindicated with history of ACEI-angioedema

Treatment Principle II: Preload Reduction - Diuretics

Loop diuretics (furosemide, torsemide, bumetanide)
  • Mechanism: Inhibit Na+-K+-2Cl- symporter in thick ascending limb of loop of Henle; increase urinary Na+/water → reduce filling pressures (preload)
  • Clinical use: Essential for symptom relief in congested patients. No proven mortality benefit but ethically impermissible to withhold
  • Key issues:
    • Diuretic resistance: add thiazide ("sequential nephron blockade")
    • Hypokalemia/hypomagnesemia → arrhythmias
    • Activates RAAS (reinforces the need for neurohormonal blockade)
    • Avoid in non-congested patients (activates RAAS, worsens outcomes)
MRAs - Spironolactone / Eplerenone
  • Mechanism: Competitive antagonism of aldosterone receptor; K+-sparing diuretic + anti-fibrotic/anti-remodeling effects
  • Evidence: RALES trial (spironolactone 25 mg in NYHA III-IV) - 30% mortality reduction; EMPHASIS-HF (eplerenone in NYHA II) - 37% reduction in primary endpoint
  • Adverse effects: Hyperkalemia, gynecomastia (spironolactone only; eplerenone is selective MRA)

Treatment Principle III: Afterload Reduction

  • Hydralazine (arterial vasodilator) + isosorbide dinitrate (venodilator) - particularly in African Americans (A-HeFT trial); also used when ACEIs/ARBs not tolerated

Treatment Principle IV: Increasing Cardiac Contractility (Inotropes)

Digoxin
  • Mechanism: Inhibits Na+/K+-ATPase → ↑ intracellular Na+ → ↑ intracellular Ca2+ via Na+/Ca2+ exchange → positive inotropy
  • Also: Reduces HR via vagal stimulation (AV node slowing)
  • Evidence: DIG trial - reduces hospitalizations but NOT mortality; only considered in patients symptomatic despite optimal neurohormonal therapy
  • Narrow therapeutic index (0.5-0.9 ng/mL); toxicity worsened by hypokalemia
  • Avoided in: WPW syndrome, hypertrophic obstructive cardiomyopathy (HOCM)
Acute/Decompensated HF - Positive Inotropes (short-term only):
  • Dobutamine (beta-1 agonist) - increases cAMP, increases contractility
  • Milrinone (PDE-3 inhibitor) - increases cAMP by reducing breakdown; vasodilator + inotrope ("inodilator")
  • Levosimendan - calcium sensitizer; sensitizes troponin C to Ca2+ without increasing intracellular Ca2+ (less arrhythmogenic)

Treatment Principle V: Heart Rate Reduction

Beta-blockers:
  • Drugs: Carvedilol, bisoprolol, metoprolol succinate (evidence-based trio)
  • Mechanism: Block SNS-mediated tachycardia and catecholamine toxicity on myocardium; reduce ischemia, arrhythmias, and remodeling
  • Evidence: MERIT-HF (metoprolol), CIBIS-II (bisoprolol), COPERNICUS (carvedilol) - each showed ~35% mortality reduction
  • Important: Start only in STABLE, euvolemic patients at very low doses; titrate slowly. Acute decompensated HF is a contraindication to initiation
  • Carvedilol also has alpha-1 blocking activity (vasodilation) and antioxidant properties
Ivabradine:
  • Mechanism: Blocks If (HCN channel) in SA node, reduces heart rate without affecting inotropy or BP
  • Indication: HR > 70 bpm in sinus rhythm despite maximum beta-blocker dose; NYHA II-IV HFrEF; SHIFT trial showed significant reduction in hospitalization
  • Contraindicated in AF/flutter (no AV nodal effect), sick sinus syndrome

Treatment Principle VI: SGLT2 Inhibition

Empagliflozin, Dapagliflozin
  • Mechanism: Inhibit SGLT2 in PCT → glucosuria + osmotic natriuresis → reduced preload/afterload; also reduce inflammation, fibrosis, and improve myocardial energetics
  • Evidence: EMPEROR-Reduced (empagliflozin), DAPA-HF (dapagliflozin) - both showed significant reduction in CV death/hospitalization regardless of diabetes status
  • Also benefit in HFpEF (EMPEROR-Preserved, DELIVER trials)
  • Now standard of care in both HFrEF and HFpEF (4th pillar alongside ACEI/ARNI, beta-blocker, MRA)

Summary Table: "Fantastic Four" (Mortality-Reducing Drugs in HFrEF)

Drug ClassExampleMechanismTrial Evidence
ACEI/ARB/ARNISacubitril-valsartanRAAS blockade + neprilysin inhibitionPARADIGM-HF
Beta-blockerCarvedilol, bisoprololSNS blockade, anti-remodelingCOPERNICUS, CIBIS-II
MRAEplerenoneAldosterone blockade, anti-fibrosisRALES, EMPHASIS-HF
SGLT2 inhibitorEmpagliflozinNatriuresis, cardioprotectionEMPEROR-Reduced
LAQ 2. Write a detailed note on the pharmacology of Calcium Channel Blockers (CCBs) in hypertension and heart failure. (10 marks)
Answer:

Classification

Dihydropyridines (DHP):
  • Examples: Amlodipine, nifedipine, felodipine, nimodipine, nicardipine
  • Predominantly act on vascular smooth muscle
  • Preferred for hypertension, Raynaud's phenomenon, stable angina
Non-Dihydropyridines:
  • Phenylalkylamine: Verapamil - most cardiac selective (SA/AV node)
  • Benzothiazepine: Diltiazem - intermediate (cardiac + vascular)

Mechanism of Action

All CCBs block L-type voltage-gated Ca2+ channels in:
  • Vascular smooth muscle → vasodilation → reduced peripheral resistance → lowered BP
  • Cardiac myocytes → reduced contractility (non-DHPs > DHPs)
  • SA/AV nodes → reduced automaticity and conduction velocity (verapamil > diltiazem > DHPs)

Uses in Hypertension

  • First-line for uncomplicated hypertension, particularly in elderly and Black patients (whose hypertension is often renin-independent)
  • Amlodipine is most commonly used: long half-life (~35-50 hours), once-daily, no reflex tachycardia
  • Short-acting nifedipine avoided for chronic HTN (reflex tachycardia, erratic BP control)
  • Preferred indications:
    • Elderly patients (especially isolated systolic HTN)
    • Angina + HTN (reduce both)
    • Raynaud's phenomenon
    • Peripheral artery disease (no reduction of peripheral flow unlike beta-blockers)
  • ASCOT trial: Amlodipine-based regimen superior to atenolol-based regimen for CV event reduction

Uses in Heart Failure

  • Non-DHPs (verapamil, diltiazem) are CONTRAINDICATED in HFrEF - their negative inotropic effect worsens systolic dysfunction
  • Amlodipine is the only CCB considered safe in HFrEF when needed for comorbid HTN or angina (PRAISE trial) - it does not worsen outcomes, but does not reduce mortality either
  • Verapamil can be used in HFpEF to reduce heart rate and improve diastolic filling

Adverse Effects

DihydropyridinesNon-Dihydropyridines
Peripheral edema (ankle)Bradycardia
Flushing, headacheAV block
Reflex tachycardia (short-acting)Constipation (verapamil)
Gingival hyperplasia (nifedipine)Negative inotropy (avoid in HFrEF)

Drug Interactions

  • Verapamil + beta-blockers → profound bradycardia and heart block (avoid combination)
  • Verapamil inhibits CYP3A4 → raises digoxin levels (toxic range)
  • Grapefruit juice inhibits CYP3A4 → elevated DHP levels
(Harrison's 22E; Goodman & Gilman's)
LAQ 3. Classify antihypertensive drugs and describe the pharmacology of Renin-Angiotensin-Aldosterone System (RAAS) blockers. (12 marks)
Answer:

RAAS Physiology (Brief)

Renin (from juxtaglomerular cells of kidney) converts angiotensinogen → Angiotensin I → ACE converts AngI → Angiotensin II → acts on AT1 receptors:
  • Vasoconstriction
  • Aldosterone release (Na+/water retention)
  • ADH release
  • SNS potentiation
  • Direct cardiac/vascular hypertrophy and fibrosis
  • Efferent arteriole constriction (maintains GFR)

RAAS Blockers - Classification

1. ACE Inhibitors (ACEIs)
  • Block ACE (kininase II), which converts AngI → AngII AND degrades bradykinin
  • Prodrugs (except captopril and lisinopril): enalapril → enalaprilat; ramipril → ramiprilat
  • Key drugs: Captopril (1st gen, thiol group - causes rash, loss of taste); Enalapril, Lisinopril, Ramipril (2nd gen)
  • Indications: HTN, HFrEF, post-MI LV dysfunction, CKD/proteinuria, DM
  • Contraindications: Pregnancy, bilateral RAS, angioedema history, hyperkalemia
2. Angiotensin Receptor Blockers (ARBs) - "Sartans"
  • Block AT1 receptors selectively; allow AngII to act on AT2 (vasodilatory, antiproliferative)
  • Do NOT affect bradykinin → no cough
  • Drugs: Losartan (first ARB), valsartan, irbesartan, candesartan, telmisartan, olmesartan
  • Clinical equivalence to ACEIs in most indications; preferred in ACEI-intolerant patients
  • Note: Combining ACEI + ARB is NOT recommended (renal failure, hyperkalemia risk without mortality benefit - ONTARGET trial)
3. Direct Renin Inhibitors (DRIs)
  • Aliskiren - blocks renin directly, preventing formation of AngI from angiotensinogen
  • Effective for BP lowering, but lack mortality-benefit data in heart failure
  • Not recommended with ACEIs/ARBs (combination increases adverse renal events - ALTITUDE trial)
  • Limited clinical use currently
4. Mineralocorticoid Receptor Antagonists (MRAs)
  • Spironolactone (non-selective - antiandrogen effects), Eplerenone (selective)
  • Used in resistant hypertension, primary aldosteronism, HFrEF, post-MI LV dysfunction
5. ARNI: Sacubitril/Valsartan
  • Dual action: neprilysin inhibition (↑ANP/BNP) + AT1 receptor blockade
  • Replaces ACEI/ARB in HFrEF (superior to enalapril per PARADIGM-HF)
  • Must not combine with ACEIs (angioedema risk); 36-hour washout required

Monitoring RAAS Blockers

ParameterWhy
Serum K+Hyperkalemia risk (especially with MRAs or CKD)
Serum creatinineAcute reduction in GFR (especially bilateral RAS or dehydration)
Blood pressureFirst-dose hypotension
Urine proteinMonitoring CKD response
Fetal statusACEIs/ARBs - teratogenic in 2nd/3rd trimester (fetal renal agenesis)

Clinical Pearls

  • ACEIs cause >25% rise in creatinine after initiation in bilateral RAS - STOP the drug
  • In HFrEF, ACEIs must be started at very low doses with gradual titration (monitor K+ and creatinine)
  • Sacubitril/valsartan should not be initiated in patients who have ever had ACEI-induced angioedema
  • Telmisartan (ARB) has the longest half-life (~24 hours) and PPAR-gamma agonist activity (metabolic benefit)

Quick Reference: RAAS Blocker Adverse Effects

Drug ClassKey Adverse Effect
ACEIsCough, angioedema, hyperkalemia, fetotoxicity
ARBsHyperkalemia, fetotoxicity (NO cough)
Direct renin inhibitorsDiarrhea, hyperkalemia
MRAsHyperkalemia, gynecomastia (spironolactone), menstrual irregularities
ARNIsAngioedema (less than ACEI), hypotension
(Goodman & Gilman's; Harrison's Principles of Internal Medicine 22E)

QUICK REVISION TABLES

Antihypertensive Drug Classes - Summary

Drug ClassMOAKey IndicationKey Contraindication
ThiazidesBlock NCC in DCT1st line HTN, elderlyGout, hypokalemia, GFR<30
Loop diureticsBlock NKCC2 in LoHHF congestion, CKD
ACE inhibitorsBlock AngI→AngII, ↑bradykininHTN, HFrEF, DM nephropathyPregnancy, bilateral RAS, angioedema
ARBsBlock AT1 receptorACEI intolerant, HTN, HFrEFPregnancy, bilateral RAS
CCBs (DHP)Block L-type Ca2+ in vesselsHTN, angina, elderly, Raynaud's
CCBs (non-DHP)Block L-type Ca2+ in heartHTN + rate control, SVTHFrEF, AV block, with beta-blockers
Beta-blockersBlock beta-1/2 adrenoceptorsHFrEF, post-MI, HTN, anginaAsthma, AV block, decompensated HF
MRAsBlock aldosterone receptorHFrEF, resistant HTN, Conn'sHyperkalemia, renal failure
Alpha-blockersBlock alpha-1, vasodilateBPH + HTNFirst-dose hypotension, HF
SGLT2iBlock glucose/Na reabsorptionHFrEF, HFpEF, DMUTI, DKA, eGFR<20

"4 Pillars" of HFrEF Mortality Reduction (GDMT)

PillarDrugTrial
RAAS blockadeACEI/ARB → best = sacubitril/valsartanPARADIGM-HF
SympatholysisCarvedilol / Bisoprolol / Metoprolol succinateCOPERNICUS, CIBIS-II, MERIT-HF
Aldosterone blockadeSpironolactone / EplerenoneRALES, EMPHASIS-HF
SGLT2 inhibitionEmpagliflozin / DapagliflozinEMPEROR-Reduced, DAPA-HF
Sources: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14e (Ch. 33); Harrison's Principles of Internal Medicine 22E (Ch. 283, 288); Braunwald's Heart Disease (Ch. 2); Brenner & Rector's The Kidney
This is a shared conversation. Sign in to Orris to start your own chat.